Ovid Therapeutics (OVID) Earnings Date, Estimates & Call Transcripts $0.32 0.00 (-0.65%) As of 11:35 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Ovid Therapeutics Earnings Summary Ovid Therapeutics posted Q1 2025 earnings on May 13, 2025, reporting an EPS of -$0.14, which met analysts' consensus estimates of -$0.14. Quarterly revenue was reported to be $0.13 million, above analyst estimates of $0.03 million. With a trailing EPS of -$0.35, Ovid Therapeutics' earnings are expected to decrease next year, from ($0.40) to ($0.64) per share. Upcoming Q2 Earnings DateAug. 12Before Market OpensEstimatedConsensus EPS (May. 13) -$0.14 Actual EPS (May. 13) -$0.14 Actual Revenue (May. 13) $0.13MQ1 2025 Earnings ResourcesQ1 2025 Earnings Report Quarterly Report (10-Q) Press Release (8-K)OVID Upcoming EarningsOvid Therapeutics' next earnings date is estimated for Tuesday, August 12, 2025, based on past reporting schedules. Powered by Get Ovid Therapeutics Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Ovid Therapeutics and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataOVID Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.OVID Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ovid Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20253-$0.13-$0.13-$0.13Q2 20254-$0.16-$0.14-$0.15Q3 20254-$0.16-$0.12-$0.14Q4 20254-$0.17-$0.12-$0.14 FY 2025 15 -$0.62 -$0.51 -$0.57 Q1 20263-$0.17-$0.11-$0.14Q2 20263-$0.17-$0.09-$0.14Q3 20263-$0.19-$0.10-$0.14Q4 20263-$0.21-$0.11-$0.16 Ovid Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails 8/12/2025(Estimated)--------5/13/2025Q1 2025-$0.14-$0.14--$0.14$0.03M$0.13M3/11/2025Q4 2024-$0.16-$0.13+$0.03-$0.13$0.19M$0.08M11/12/2024--$0.19-$0.20 -$0.01-$0.20$0.15M$0.17M8/13/2024Q2 2024-$0.22$0.12+$0.34$0.12$0.14M$0.17M5/14/2024Q1 2024-$0.23-$0.17+$0.06-$0.17$0.11M$0.15M3/8/2024Q4 2023-$0.17-$0.22 -$0.05-$0.22$0.10M$0.14M11/3/2023Q3 2023-$0.18-$0.16+$0.02-$0.16$0.09M$0.11M8/4/2023Q2 2023-$0.21-$0.18+$0.03-$0.18$0.09M$0.08M Ovid Therapeutics Earnings - Frequently Asked Questions When is Ovid Therapeutics's earnings date? Ovid Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, August 12th, 2025 based off last year's report dates. Learn more on OVID's earnings history. Did Ovid Therapeutics beat their earnings estimates last quarter? In the previous quarter, Ovid Therapeutics (NASDAQ:OVID) reported ($0.14) earnings per share (EPS) to hit the analysts' consensus estimate of ($0.14). Learn more on analysts' earnings estimate vs. OVID's actual earnings. How much revenue does Ovid Therapeutics generate each year? Ovid Therapeutics (NASDAQ:OVID) has a recorded annual revenue of $548,000.00. How much profit does Ovid Therapeutics generate each year? Ovid Therapeutics (NASDAQ:OVID) has a recorded net income of -$52.34 million. OVID has generated -$0.35 earnings per share over the last four quarters. What is Ovid Therapeutics's EPS forecast for next year? Ovid Therapeutics's earnings are expected to decrease from ($0.40) per share to ($0.64) per share in the next year. More Earnings Resources from MarketBeat Related Companies JSPR Earnings Results GALT Earnings Results SNTI Earnings Results UNCY Earnings Results CLYM Earnings Results STRO Earnings Results EPIX Earnings Results PYXS Earnings Results ADAP Earnings Results IGMS Earnings Results Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Broadcom Slides on Solid Earnings, AI Outlook Still StrongFive Below Pops on Strong Earnings, But Rally May StallRed Robin's Comeback: Q1 Earnings Spark Investor HopesOllie’s Q1 Earnings: The Good, the Bad, and What’s NextBroadcom Earnings Preview: AVGO Stock Near Record HighsUlta’s Beautiful Q1 Earnings Report Points to More Gains Aheade.l.f. Beauty Sees Record Surge After Earnings, Rhode Deal This page (NASDAQ:OVID) was last updated on 6/11/2025 by MarketBeat.com Staff From Our PartnersTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ovid Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ovid Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
